|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Procainamide#Adult Indications and Dosage]] |
| {{Procainamide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| | |
| Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular [[tachycardia]], that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser [[arrhythmias]] generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided.
| |
| | |
| Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital.
| |
| | |
| Antiarrhythmic drugs have not been shown to enhance survival in patients with [[ventricular arrhythmias]].
| |
| | |
| Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.)<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PROCAINAMIDE HYDROCHLORIDE INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17e47845-daad-434c-a784-6d3875b0d704 | publisher = | date = | accessdate = 11 March 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Antiarrhythmic agents}}
| |
| | |
| [[Category:Benzamides]]
| |
| [[Category:Anilines]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |